A model of type-2 diabetes mellitus (T2DM) using high-fat diet and low-dose STZ was established to assess the antidiabetic effects of Auricularia auricular polysaccharides simulated hydrolysates (AAPHs) obtained from the dried fruiting body of A. auricular. AAPHs were administered intragastrically (i.g.) at the dose of 0.15 g/kg b. W. to diabetic Wistar rats for 4 weeks. Results show that AAPHs was demonstrated to exhibit significant diminution in T-CHO and LDL-C levels (P < 0.05 or P < 0.01) compared to the diabetic control group. In addition, the secretion level of GLP-1 were different with the diabetes model group from 0 to 30 min, and had a tendency to alleviate weight loss. The current study suggests that AAPHs might be incorporated as a supplement in diabetic agents or combined with other health-care foods.
Diabetes mellitus (DM), as a major global health problem, is one of the most common chronic and metabolic disorder diseases, which is a serious damage to human health and even life threatening. There has been a sharp increase across the world in recent decades, in 2012 diabetes was the direct cause of 1.5 million deaths, and more than 80% of diabetes deaths occur in low-and middle-income countries [1] . 90% of the diabetes cases are T2DM which is characterized by insulin resistance and impaired insulin secretion due to islet β cells dysfunction [2] . For As for DM therapy, there have been a series of synthetic agents., However, continuous use of synthetic anti-diabetic drugs is associated with side-effects and toxicity [3] . Even as new classes of oral anti-diabetic drugs are being developed and designed, such as DPP-4 inhibitors, GLP-1 analogs and SGLT-2inhibitors, establishing a diet-based approach to delay or completely prevent the need for such anti-diabetic medication would be a useful adjunct [4] [5] .
Auricularia auricula is a precious edible and medicinal mushroom which was used in Traditional Chinese Medicine for more than 1000 years [6] . The fruit bodies of A. auricula are a kind of blackbrown fungus with high contents of carbohydrates (approximately 630 g kg -1 in dried fruit bodies) [7] , and this species is the fourth most important cultivated mushroom that is used by humans all over the world [8] . Nowadays a great number of studies on fresh and dried Auricularia auricula-judae polysaccharides have confirmed that they possesses a large variety of biological functions, including hypoglycemic [9] [10] [11] , antitumor [12] , hypolipidemic [13] [14] , antiviral [15] , anticoagulant [16] , antioxidant [17] [18] [19] and immuno-enhancing [20] activities.
Recent studies illustrated that natural polysaccharides demonstrating their physiological activities to animals by oral administration are correlated to the oligosaccharide derivatives produced by gastric acid or enzymes in digestive tract [21] [22] . As it is well known that hydrolysis of polysaccharide with acid can break off the glycosidic bond, and generating the less molecular oligosaccharides. There may be one or more oligosaccharide fragments as the active centers in the polysaccharide molecules.
Several report have shown that the derived oligosaccharides produced by the acid or enzymatic hydrolysis polysaccharides can be used as antioxidant or prebiotic [23] [24] [25] . Auricularia auricula is a traditional Chinese medicinal mushroom widely used as a clinical treatment in the form of the fruiting body or crude polysaccharides. However, to date, there is little published information concerning the potential anti-diabetic effect of the polysaccharide hydrolysate obtained from this mushroom. The aims of this study were to prepare the simulated hydrolysate (AAPHs) from A. auricula polysaccharides (AAPHs) by using artificial simulated gastric fluid and to evaluate the antidiabetic potential of these hydrolyzed products.
R T change of A. auricula polysaccharides after artificial gastric digestion in vitro: As shown in Figure 1 , there were some differences in R T at different time points throughout the artificial simulated gastric fluid hydrolysis. As the hydrolysis time went on, the chromatogram peak was also increasing. Specifically, the peak increased from 1 to 3 in the first 15 minutes of gastric digestion, then the number of peaks and R T remained unchanged after 15 minutes of hydrolysis.
These results showed that A. auricula polysaccharides could be degraded to oligosaccharide fragments to some extent in the environment of simulated gastric digestion in vitro. Thus, the hydrolysates were prepared during the reaction of 30min in simulated gastric fluid, and used for the following experiments after dialysis.
The average molecular weight of peak 1, 2 and 3 of AAPHs were determined by HPGPC. A standard curve was prepared by different molecular weight of dextrans. The standard equation Log Mw =0.4496TR + 10.734 (R2=0.9972). Peak 1, 2 and 3 were eluted as a single symmetrical peak, as determined by HPGPC in Figure 1 , which showed that peak 1, 2 and 3 of AAPHs were homogeneous and purified. According to the calibration curve, the molecular weight of peak 1, 2 and 3 of AAPHs were listed at Figure 2 .
It was reported that low dose injection of STZ could result in the apoptosis of islet cell while high dose induced necrosis that mainly mimick T1DM [28] . HFD was the vital point in inducing insulin resistance, meanwhile low dose STZ damaged partial islet cells similar with T2DM in human [29] . As we expected, the rats fed a HFD and administered a low dose of STZ had significantly increased levels of FBG, establishing that T2DM model was successfully developed.
From the experimental data in Figure 2 , FBG level of control group (Normal) showed an inappreciable change during the experimental period (between 4.40 and 4.88 mmol/L), and a stable hyperglycaemia model formed after HFD and low-dose STZ injection. FBG values were about 4 folds higher in all the diabetic groups in comparison to normal control. There were no significant differences in FBG levels (p > 0.05) among the diabetic groups, although there was a significant difference (p < 0.01) compared to Effect of AAPHs on OGTT in T2DM rats: After AAPHs treatment for 4 weeks, glucose tolerance was examined in 4 experimental groups using OGTT methodology. Figure 3 showed the changes in the levels of blood glucose during OGTT (2 g glucose/kg body weight). The glucose tolerance was impaired in the diabetic group, and it showed an increase in fasting blood glucose (FBG) level at 30min and remained higher evidently over next 90min after oral glucose administration compared to the nondiabetic control group. In contrast, glucose blood levels remained higher in the diabetic control group throughout the period studied, while AAPHs group caused a reduction of 14.6% in the blood glucose level measured 120 min after the administration of glucose, compared with the diabetic control rats. And the diabetes + acarbose group was statistically significant (p < 0.05) 120 min after the administration of glucose, compared with the diabetes model group. Improvement the impaired OGTT of T2DM rats following acarbose treatment was also observed. The insulin resistant (IR) is a crucial pathophysiological factor in the development and progression of diabetes [30] , and IR state of T2DM rats is confirmed by severely impaired glucose tolerance [31] . AAPHs treatment showed some improvement in oral glucose tolerance in HFD and low-dose STZ induced T2DM, this suggest that AAPHs might improves insulin resistance to an extent.
Effect of AAPHs on GLP-1 secretion levels in T2DM rats:
To investigate changes in plasma GLP-1 of diabetic rats after AAPHs treatment, GLP-1 secretion curve were performed during the last week of treatment. Glucagon-like peptide-1 (GLP-1), a glucoincretin hormone that augments glucose-dependent insulin secretion, has gained widespread usage owing to its effective glucose-lowering actions [32] . As shown in Figure 4 , GLP-1 secretion was impaired in the diabetic group, and it showed an decrease during the experimental period after oral glucose administration compared to the nondiabetic control group. Whereas AAPHs group caused a significant increment of GLP-1 level (P < 0.05) compared to the diabetic control group from 0 min to 30 min, but no significant difference was observed at 60 min. GLP-1 can promote islet β cells to secrete insulin and reduce islet α cells to secrete glucagon which relied on glucose concentration [33] . These results indicated that AAPHs could partly restore apoptosis in pancreatic islet cells induced by STZ.
Changes in body weight and clinical sign:
The effect of AAPHs on the body weight changes of the experimental rats was shown in Table 2 . Table 2 : Changes in body weight (g) of rats from different groups.
Data represent the means±S.D. "**", p < 0.01, compared to the negative group, n = 5.
Before the experiment, all the groups had no significant difference in body weight (P > 0.05). Compared to the normal control rats, all the un-treated diabetic model rats exhibited significant (P < 0.05) loss of body weight during the whole experiment period. A significant reduce in body weight was detected in the positive control, diabetic model and AAPHs groups as compared to the normal control group from 0 week after the model of T2DM established (P < 0.05). Although there was no significant difference in body weight (P > 0.05) among this three groups, the body weights in the diabetic model groups kept decreasing, while the positive control and AAPHs groups had gone up again from 3 weeks after administration. This fact suggests that AAPHs could help rats recover their body weight even after developing diabetes.
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observed. The hair of the diabetic model rats lost its luster and showed obvious thinning symptoms, and these animals increased feed intake, water intake and urination, these were typical symptoms of diabetes in untreated rats. From the treatment with acarbose and AAPHs, it was noted that these clinical sign were able to improve greatly compared with the diabetes model group.
The present study revealed that AAPHs had no significant impact on body weight of diabetic rats, but the body weight loss could be relieved. In the current study, the rats induced with HFD and lowdose STZ developed diabetes signs including polydipsia, polyphagia, polyuria and body weight loss. The body weight loss was probably due to the increased rate of proteolysis and lipolysis for glucose generation in the diabetic state which leads to muscle wasting and loss of adipose tissue [34] . Supplementation with AAPHs to diabetic rats might have a tendency to alleviate weight loss.
Effects of AAPHs on serum lipids levels in T2DM rats:
The results of AAPHs on serum lipids levels of diabetic rats induced by HFD and low-dose STZ were shown in Table 3 . Values are expressed as means ±SD (n=5). *p < 0.05 significant from the diabetic control, **p < 0.01 significant from the diabetic control.
As shown in Table 3 , serum TG and LDL-C levels in diabetic model rats were significantly increased, and HDL-C levels were significantly decreased compared to normal control rats. TG level in diabetic model group was higher compared to the other three groups of rats. Administration of AAPHs for 4 weeks to diabetic rats resulted in significant diminution in T-CHO and LDL-C levels compared to the diabetic model group (P < 0.05 or P < 0.01). It has been known that diabetes is considering as a disease of lipid metabolism disturbance more than carbohydrate [35] . Our results showed that AAPHs evoked remarkable improvement in hyperglycemia and hyperlipidemia as well as glucose tolerance after 4 weeks of administration, and exhibits potent and efficacious hypoglycemic and hypolipidemic effects in T2DM rats.
Conclusions:
Auricularia auricular polysaccharides simulated hydrolysates (AAPHs), obtained from the dried fruiting body of A. auricular, were a variety of natural fungal polysaccharides. By using HFD and low-dose STZ induced male wistar rats as T2DM model, administration of AAPHs could resulted in significant diminution in T-CHO and LDL-C levels (P < 0.05 or P < 0.01) compared to the diabetes group. The blood glucose level caused a reduction of 14.6% compared with the diabetic control rats, 120 min after the administration of glucose. In addition, the secretion level of GLP-1 were different with the diabetes model group from 0 to 30min, and had a tendency to alleviate weight loss. The current study demonstrates that AAPHs might have a potential for the treatment of hyperglycemia and hyperlipidemia. In conclusion, to the best of our knowledge, there are few reports on the antihyperglycemic and antihyperlipidemic effects of A. auricular polysaccharides simulated hydrolysates on HFD and low-dose STZ induced diabetic rats. Studies on the influence of AAPHs on other signaling pathways and associated gene expression are still in progress.
Experimental
Materials and chemicals: Auricularia auricula was purchased from a farmer's market (Daxinganling, Helongjiang, China). The fruiting bodies of A. auricula were washed and oven dried in a hot air oven (DHG-9023AD, China) at 70℃ to a constant weight. Then, they were pulverised to a particle diameter size of 200-300 μm and stored in a desiccator at room temperature.
STZ, pepsin (1:10000), α-amylase and pancreatin (1:4000) were purchased from Sigma Chemical Co. (St Louis, MO, USA).
Acarbose (biological pure), purchased from Nanjing Duly Biotech Co., Ltd (Nanjing, Jiangsu Province, China). Test kits for the followings were obtained from Nanjing Jiancheng Bioengineering Institute (Nanjing, Jiangsu Province, China): total cholesterol (TC), total triglyceride (TG), high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c). ELISA detection kit for GLP-1 was provided by Shanghai Qiyi Biotechnology Company (Shanghai, China). A one-touch glucometer was purchased from Roche Diagnostics GmbH (Mannheim, Germany) for the analysis of blood glucose (BG). All other chemicals were of analytical grade and obtained from commercial sources.
Preparation of A. auricula polysaccharides hydrolysates:
A. auricula powders (10 g) were homogenized in 1.6 L of a 1% (w/v) sodium hydroxide solution and stirred for 3 h at 80 °C. Then hydrochloric acid was added to adjust the pH to 7.0. The samples were clarified by centrifugation at 8000 rpm for 10 min. The supernatants were collected, precipitated with 95% ethanol (1 : 4, v/v) overnight at 4 °C and then centrifuged at 5000 rpm for 10 min. The precipitate was re-dissolved in distilled water. Deproteinization was performed with 1/5th the volume of the sample of the Sevag reagent (butyl alcohol : chloroform = 1 : 4, v/v). This treatment was repeated until there was no absorption at 280 nm on the UV-Vis spectrophotometer.
The obtained sample (10 mg/mL, 100 mL) was added to a solution of simulated gastric medium (150 mL, pH 1.5), and the final pH value was adjusted to 2.5±0.2 by addition of HCl (1M). The simulated gastric medium was composed of HCl (37 mM), NaCl (37 mM), KH 2 PO 4 (4.6 mM), CaCl 2 (1.1 mM), KCl (5.2 mM), and pepsin (0.50 g/l) [26] . The sample was hydrolyzed at 37 °C for 5, 10, 15, 20, 30, 60, 90, 120, 150, 180 and 210 mins, respectively, then the hydrolysate was immediately added NaOH (1M) to neutralize it, and centrifuged with a flow centrifuge at 10,000 rpm for 10min at 4°C. The supernatant was collected and passed through an ultrafiltration cell with membrane pores of 3.5 kDa. The residual material, with a molecular mass above 3.5 kDa, was collected and lyophilised to obtain A. auricula polysaccharides hydrolysates (AAPHs).
General analytical methods:
The hydrolysis degrees of A. auricula polysaccharides at different time points was analysed by highperformance liquid chromatography (HPLC). The chromatographic system for the analysis included a LC-20AD pump (Shimadzu, Japan), a RID-10A refractometer (Shimadzu, Japan) as a detector and a TSK G3000 SW XL column (7.8 mm × 30 cm). The HPLC experiments were performed with a flow rate of 0.6 ml/min. The column was equilibrated with ultrapure water, and the elution was carried out with the same solution.
Animals and their care: Adult male Wistar rats (220 ± 10 g) were provided by the animal center of Hangzhou Normal University, and maintained under a constant 12 h light-dark cycle at a temperature of 25 ± 2℃ and relative humidity ranging from 50% to 70% throughout the experimental period. They were allowed free access to water and standard laboratory diet. The experiment was approved by animal ethics guidelines of the Institutional Animal Ethics Committee. All procedures were conducted in accordance with the recommendations of the 'Guide for the Care and Use of Laboratory Animals' published by the National Institutes of Health.
Molecular weight determination:
The Mw of peak 1, 2 and 3 of AAPHs were determined by HPGPC. A TSKgel G4000SWXL (TOSOH, Japan) column (7.8 × 300 mm) and a refractive index detector (RID) of Shimadzu apparatus equipped were used. The eluent was ultrapure water and the flow rate of the water was 0.5 mL/min. The column temperature was been set at 35°C. All samples were through 0.22 μm syringe filter before passing through, and the volume of each sample was 20 μL. Seven dextran standards (Mw is 180, 505, 4300, 20100, 31200, 158100 and 291600 Da, respectively) were applied for calibration. The retention time (RT) and the logarithm of the molecular weights had a linear relationship. According to the equation of linear regression of standard curve, the Mw of sample can be calculated using RT.
Induction of T2DM rats model: T2DM model was induced by feeding rats with a high-fat diet (HFD), which prepared by adding 20% sucrose (w/w), 10% lard fat (w/w), 1% cholesterol(w/w) and 2.5% dried egg yolk powder into basal diet, for 6 weeks, then rats injected with intraperitoneal (i.p.) administration of streptozotocin (STZ) (30 mg/kg BW, freshly prepared in citric acid buffer, 0.1mol/L). This low dose STZ exhibited a slight trauma to pancreatic β cells, and the combination of HFD and low-dose STZ substituted as an alternative animal model resembling the human T2DM. All rats were allowed to have a free access to food and water until the start of the experiment. Two weeks later, all HFD and STZ-injected rats were assessed by measuring glucose levels in tail vein. Glucose levels over 15.6 mmol/L were considered as diabetic experiment animal.
Experimental design:
The rats used for the experiment were randomly divided into 4 groups (5 rats per group). The groups were Group I: normal rats as the control group and intragastric administration with saline (0.86% NaCl). Group II: HFD and STZinduced diabetic rats as the model group and intragastric administration with 0.86% NaCl only. Group III: HFD and STZinduced diabetic rats were administered acarbose at 15 mg/kg BW in 0.86% NaCl, as the positive control group. Group IV: HFD and STZ-induced diabetic rats administered 150 mg/kg BW of AAPHs by intragastric administration. The dose of AAPHs was selected based on the results of the previous study [27] .
Biochemical analysis: After 6 weeks of treatment, the rats were fasted overnight and blood glucose (BG) levels in tail vein were determined using a glucometer. Then blood samples were collected from the rat hearts and put into non-heparinized tubes for centrifuging at 3500 rpm to separate blood serum. Serum total cholesterol and triglyceride were determined using commercial total cholesterol and triglyceride assay kit (GPO-PAP single reagent microplate method), and serum HDL-C and LDL-C were determined using commercial HDL-C and LDL-C assay kit (double reagent direct method) from Nanjing Jiancheng Bioengineering Institute (Nanjing, China), respectively.
Determination of oral glucose tolerance: Oral glucose tolerance testing (OGTT) and GLP-1 secretion curve were performed at the end of the experimental period. After a 12 h fasting with free access to water, the animals in different experimental groups were intragastric administration with 0.86% NaCl, 15 mg/kg BW of acarbose and 150 mg/kg BW of AAPHs, successively. After 1 h, the animals were orally gavaged with 2 g/kg body weight of glucose dissolved in water. Then, blood samples from the tail vein and eyeball vein were collected respectively at 0, 30, 60 and 120 min after glucose loading under light ether anesthesia. Blood glucose levels were tested using a glucometer with the tail vein blood samples, and GLP-1 levels were determined using a commercial rat GLP-1 ELISA kit (QY-R2115) from Shanghai Qiyi Biotechnology Company (Shanghai, China) with eyeball vein blood samples.
Statistical analysis: Data were expressed as means±standard deviations of three replicated determinations. The statistical analyses of the data were performed with IBM SPSS Statistics 19. Turkey method which is one-way ANOVA analyses was used to detect statistical significance, and differences were considered significant when p < 0.05.
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